Quantitative Health Sciences

Medicine & Life Sciences

1. 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole 12%
2. Adenocarcinoma 11%
3. Alleles 15%
4. Alzheimer Disease 32%
5. Amyloid 24%
6. Anti-Inflammatory Agents 12%
7. Anticoagulants 15%
8. Anxiety 14%
9. Apolipoprotein E4 24%
10. Barrett Esophagus 13%
11. Biomarkers 20%
12. Body Mass Index 11%
13. Brachytherapy 12%
14. Breast 18%
15. Breast Neoplasms 72%
16. Bupropion 12%
17. Clinical Trials 26%
18. Cognition 20%
19. Cognitive Aging 15%
20. Cognitive Dysfunction 94%
21. Cohort Studies 16%
22. Colonic Neoplasms 31%
23. Colorectal Neoplasms 100%
24. Confidence Intervals 40%
25. Consensus 13%
26. Databases 11%
27. Dementia 42%
28. Depression 24%
29. Disease-Free Survival 12%
30. Drug Therapy 21%
31. Elderly 18%
32. Electronic Nicotine Delivery Systems 14%
33. Endometrial Neoplasms 11%
34. Equipment and Supplies 11%
35. Essential Thrombocythemia 13%
36. Exercise 11%
37. Fatigue 11%
38. Genes 31%
39. Genome 12%
40. Genome-Wide Association Study 19%
41. Genotype 12%
42. Germ-Line Mutation 14%
43. Glioblastoma 14%
44. Guidelines 15%
45. Health 14%
46. Hemorrhage 21%
47. Hereditary Nonpolyposis Colorectal Neoplasms 45%
48. Hispanic Americans 13%
49. human ERBB2 protein 15%
50. Immunity 14%
51. INCB018424 11%
52. Incidence 14%
53. Lapatinib 16%
54. Melanoma 15%
55. Memory 12%
56. Mortality 11%
57. Mutation 51%
58. National Cancer Institute (U.S.) 17%
59. Neoplasm Metastasis 11%
60. Neoplasms 97%
61. Non-Small Cell Lung Carcinoma 19%
62. Odds Ratio 20%
63. Ovarian Neoplasms 25%
64. Patient Reported Outcome Measures 72%
65. Pharmaceutical Preparations 11%
66. Phenotype 14%
67. Placebos 14%
68. Polycythemia Vera 20%
69. Population 36%
70. Primary Myelofibrosis 22%
71. Prospective Studies 12%
72. Prostatic Neoplasms 15%
73. Proton Therapy 22%
74. Quality of Life 39%
75. Radiation 16%
76. Radiosurgery 25%
77. Radiotherapy 44%
78. Randomized Controlled Trials 11%
79. Rectal Neoplasms 11%
80. Recurrence 17%
81. Registries 34%
82. Research Personnel 22%
83. Smokers 18%
84. Smoking 17%
85. Smoking Cessation 38%
86. Social Networking 11%
87. Survival 41%
88. Symptom Assessment 12%
89. T-Lymphocytes 26%
90. Terminology 28%
91. Therapeutics 35%
92. Tobacco 29%
93. Tobacco Products 17%
94. Tobacco Use 13%
95. Tobacco Use Cessation 18%
96. Tobacco Use Cessation Devices 15%
97. Trastuzumab 37%
98. Veterans 11%